Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

34733 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE TRUVADA

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	PAIN	2820
1	ANXIETY	2722
2	EMOTIONAL DISTRESS	2507
3	ECONOMIC PROBLEM	2490
4	ANHEDONIA	2311
5	FOETAL EXPOSURE DURING PREGNANCY	1365
6	DRUG INTERACTION	1250
7	NAUSEA	1234
8	DIARRHOEA	1218
9	FATIGUE	1101

See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	CLOACAL EXSTROPHY	24	0.5581
1	ACUTE HIV INFECTION	80	0.5479
2	HIV VIRAEMIA	16	0.5333
3	FEAR-RELATED AVOIDANCE OF ACTIVITIES	31	0.5000
4	SPINOCEREBELLAR DISORDER	17	0.4474
5	BLOOD HIV RNA	14	0.4000
6	BLADDER AGENESIS	25	0.3906
7	HYPERANDROGENISM	21	0.3500
8	CSF VIRUS IDENTIFIED	21	0.3387
9	BLOOD HIV RNA INCREASED	243	0.3356

See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]